BridgeBio Pharma Inc (BBIO) — Financial Flexibility Index
BridgeBio Pharma Inc (BBIO) has a Financial Flexibility Index of -0.04x as of September 2025. Free cash flow of $-109.10 Million (operating CF $-109.57 Million minus capex $470.00K) represents 0% of total liabilities ($2.92 Billion). Check BridgeBio Pharma Inc investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
BridgeBio Pharma Inc Financial Flexibility Index (2017–2024)
Historical Financial Flexibility Index trend for BridgeBio Pharma Inc across 8 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of BridgeBio Pharma Inc.
Annual Financial Flexibility Index for BridgeBio Pharma Inc (2017–2024)
Year-by-year free cash flow to debt coverage for BridgeBio Pharma Inc. Explore BridgeBio Pharma Inc cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -0.22x | $-519.79 Million | $-520.73 Million | $2.38 Billion | ▲ +21.5% |
| 2023 | -0.28x | $-526.41 Million | $-527.72 Million | $1.89 Billion | ▼ -26.0% |
| 2022 | -0.22x | $-413.17 Million | $-419.49 Million | $1.87 Billion | ▲ +7.6% |
| 2021 | -0.24x | $-449.69 Million | $-497.93 Million | $1.88 Billion | ▲ +63.6% |
| 2020 | -0.66x | $-392.20 Million | $-399.71 Million | $595.70 Million | ▲ +58.7% |
| 2019 | -1.60x | $-248.45 Million | $-253.59 Million | $155.70 Million | ▼ -663.0% |
| 2018 | -0.21x | $-118.47 Million | $-136.64 Million | $566.44 Million | ▲ +20.2% |
| 2017 | -0.26x | $-40.02 Million | $-40.49 Million | $152.73 Million | — |